Walvax Biotechnology Co (SZSE:300142) Interest Expense : ¥-8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Walvax Biotechnology Co's interest expense for the three months ended in Mar. 2024 was ¥ -3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Walvax Biotechnology Co's Operating Income for the three months ended in Mar. 2024 was ¥ 147 Mil. Walvax Biotechnology Co's Interest Expense for the three months ended in Mar. 2024 was ¥ -3 Mil. Walvax Biotechnology Co's Interest Coverage for the quarter that ended in Mar. 2024 was 43.49. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Walvax Biotechnology Co Interest Expense Historical Data

The historical data trend for Walvax Biotechnology Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Interest Expense Chart

Walvax Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-30.56

-0.60

-5.77

-7.11

-5.95

Walvax Biotechnology Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.28	-1.45	-1.03	-2.19	-3.38

Walvax Biotechnology Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-8 Mil.

Walvax Biotechnology Co (SZSE:300142) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Walvax Biotechnology Co's Interest Expense for the three months ended in Mar. 2024 was ¥-3 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥147 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ¥448 Mil.

Walvax Biotechnology Co's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	147.075	/	-3.382
	=	43.49

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Walvax Biotechnology Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Walvax Biotechnology Co (SZSE:300142) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106

Website

http://www.walvax.com

Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.

Executives

Wu Yun Yan	Executives
Zhao Jin Long	Executives
Yao Wei	Executives
Zhou Hua	Executives
Shi Jing	Executives
Jiang Run Sheng	Directors, executives
Gong Sun Qing	Executives
	Executives
Yuan Lin	Executives
Fang Guo Liang	Executives
Li Yun Chun	Director
Huang Zhen	Director
Zhang Li	Secretary Dong
Yang Hong Wei	Supervisors
Xu Ke Ren	Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines